The ARRB2 Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Jurkat T lymphocyte cell line. This product features disruption of the ARRB2 gene, encoding beta-arrestin-2, and is supplied as a polyclonal population to provide a heterogeneous loss-of-function model. The cells are generated using CRISPR/Cas9-mediated gene disruption without clonal selection, enabling studies that average effects across multiple edited alleles while maintaining the biological variability inherent to a polyclonal pool.
Jurkat cells are an immortalized T lymphocyte line established from the peripheral blood of a 14-year-old male with acute T cell leukemia. This widely used model retains key features of human T cell signaling, including T cell receptor (TCR)-mediated activation, cytokine production, and apoptosis regulation. As a suspension cell line expressing various G protein-coupled receptors (GPCRs) and components of MAPK and NF-??B pathways, Jurkat cells provide a physiologically relevant background for dissecting GPCR and immune signaling mechanisms.
The ARRB2 gene product, beta-arrestin-2, is a key scaffold protein that mediates GPCR desensitization and G protein-independent signaling. Following GRK-mediated phosphorylation of activated GPCRs such as CXCR4 and the ??2-adrenergic receptor, beta-arrestin-2 is recruited, promoting desensitization and clathrin-mediated endocytosis via interactions with AP-2 and clathrin. It scaffolds MAPK cascade components Raf, MEK, ERK1/2, JNK, and p38, and modulates downstream effectors Akt, NF-??B p65, and ??-catenin. Additionally, beta-arrestin-2 interacts with c-Src, MDM2, PDE4, and I??B??, linking GPCR activation to proliferation, survival, and cytokine expression.
In Jurkat cells, ARRB2 knockout disrupts the normal desensitization and internalization of endogenously expressed GPCRs, such as CXCR4, and impairs beta-arrestin-2-mediated scaffolding of MAPK and NF-??B signaling downstream of the TCR and other receptors. This leads to altered TCR-mediated ERK1/2 phosphorylation, NF-??B transcriptional activity, and cytokine gene expression, as well as modified apoptotic responses. Consequently, this knockout model is particularly valuable for investigating the role of beta-arrestin-2 in T cell leukemia biology, biased GPCR signaling, and the crosstalk between GPCR and immune receptor pathways.
These polyclonal ARRB2 knockout Jurkat cells are suitable for biased GPCR ligand screening, phospho-ERK western blotting to examine scaffold-dependent MAPK regulation, NF-??B luciferase reporter assays, and apoptosis studies via Annexin V flow cytometry. GPCR internalization assays and cytokine qPCR profiling further enable linking beta-arrestin-2 loss to immune cell function. The model also supports cancer drug target validation in T cell leukemia contexts. For further details, contact Ascent Research.
